Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Responds On Meridia: Morbidity Standard Is Unworkable

Executive Summary

Weight-loss drugs such as Meridia would never come to market if approvals are based on demonstrating a reduction in morbidity and mortality, Abbott maintains

You may also be interested in...



Meridia Growth Forecast Is 50% In 2002, Despite Italian Withdrawal – Abbott

Abbott's revised forecast for the anti-obesity agent Meridia (sibutramine) still assumes a 50% increase in worldwide sales for 2002

Meridia Growth Forecast Is 50% In 2002, Despite Italian Withdrawal – Abbott

Abbott's revised forecast for the anti-obesity agent Meridia (sibutramine) still assumes a 50% increase in worldwide sales for 2002

Meridia Fatality Rate “Substantially Lower” Than Obese Population – Abbott

Abbott's Meridia patient fatality rate is "substantially lower" than what would generally be expected from the obese population, the company maintains in response to a Public Citizen Health Research Group petition calling for the drug's withdrawal

UsernamePublicRestriction

Register

PS039763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel